CD274 and neoplasm: In an additional study using a syngeneic subcutaneous PC mouse model, the anti-tumor properties of gemcitabine (60 μg/g Q3D, 0–2 weeks) were enhanced by combining with delayed 2-week PD-L1 blockade (0.3 mg TIW, 2–4 weeks).